A Phase 2, Multiple-Dose, Pharmacokinetic and Pharmacodynamic Study of RDEA594 in Gout Patients with Hyperuricemia and Gout with Renal Insufficiency

Registry ID

EUCTR2009-014762-26

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Ardea Biosciences, Inc.

Start date

2009-10-27

Last update

2026-08-16

Conditions

• Gout.

Summary

To determine the safety profile of orally administered RDEA594 alone or as an add-on to ongoing allopurinol treatment in gout patients with moderate renal insufficiency.

Locations

• , , Belgium

View on source registry